Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and
maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The
expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in
patients with advanced metastatic melanoma.